China Resources Pharmaceutical Group Ltd
HKEX:3320
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
HK |
|
Embla Medical hf
CSE:EMBLA
|
IS |
Wall Street
Price Targets
Price Targets Summary
China Resources Pharmaceutical Group Ltd
According to Wall Street analysts, the average 1-year price target for China Resources Pharmaceutical Group Ltd is 6.65 HKD with a low forecast of 5.42 HKD and a high forecast of 9.24 HKD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is China Resources Pharmaceutical Group Ltd's stock price target?
Price Target
6.65
HKD
According to Wall Street analysts, the average 1-year price target for China Resources Pharmaceutical Group Ltd is 6.65 HKD with a low forecast of 5.42 HKD and a high forecast of 9.24 HKD.
What is China Resources Pharmaceutical Group Ltd's Revenue forecast?
Projected CAGR
7%
For the last 11 years the compound annual growth rate for China Resources Pharmaceutical Group Ltd's revenue is 6%. The projected CAGR for the next 2 years is 7%.
What is China Resources Pharmaceutical Group Ltd's Operating Income forecast?
Projected CAGR
9%
For the last 11 years the compound annual growth rate for China Resources Pharmaceutical Group Ltd's operating income is 5%. The projected CAGR for the next 2 years is 9%.
What is China Resources Pharmaceutical Group Ltd's Net Income forecast?
Projected CAGR
4%
For the last 11 years the compound annual growth rate for China Resources Pharmaceutical Group Ltd's net income is 4%. The projected CAGR for the next 2 years is 4%.